Skip to main content
SpringerLink
Log in

Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma

  • Special Section: HCC Treatment
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Transarterial radioembolization with yttrium-90 microspheres is an established therapy for hepatocellular carcinoma. Post-procedural imaging is important for the assessment of both treatment response and procedural complications. A variety of challenging treatment-specific imaging phenomena complicate imaging assessment, such as changes in tumoral size, tumoral and peritumoral enhancement, and extrahepatic complications. A review of the procedural steps, emerging variations, and timelines for post-treatment tumoral and extra-tumoral imaging changes are presented, which may aid the reporting radiologist in the interpretation of post-procedural imaging. Furthermore, a description of post-procedural complications and their significance is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.

    Article  PubMed  Google Scholar 

  2. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol. 2001 Sep;35(3):421–30.

  3. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011 Mar;53(3):1020–2.

    Article  PubMed  Google Scholar 

  4. Riaz A. Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma. JAMA. 2010 Mar 17;303(11):1062.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R, et al. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. J Clin Med. 2019 Jan 7;8(1):55.

    Article  CAS  PubMed Central  Google Scholar 

  6. Joo I, Kim H-C, Kim GM, Paeng JC. Imaging Evaluation Following 90 Y Radioembolization of Liver Tumors: What Radiologists Should Know. Korean J Radiol. 2018;19(2):209.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016 Dec;151(6):1155-1163.e2.

  8. Zarva A, Mohnike K, Damm R, Ruf J, Seidensticker R, Ulrich G, et al. Safety of Repeated Radioembolizations in Patients with Advanced Primary and Secondary Liver Tumors and Progressive Disease After First Selective Internal Radiotherapy. J Nucl Med. 2014 Mar 1;55(3):360–6.

    Article  PubMed  Google Scholar 

  9. Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, et al. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021 Mar 1;94(1119):20200752.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Braat AJAT, Huijbregts JE, Molenaar IQ, Borel Rinkes IHM, van den Bosch MAAJ, Lam MGEH. Hepatic Radioembolization as a Bridge to Liver Surgery. Front Oncol [Internet]. 2014 Jul 30 [cited 2019 Aug 21];4. Available from: http://journal.frontiersin.org/article/10.3389/fonc.2014.00199/abstract

  11. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol. 2007 May;68(1):13–23.

    Article  Google Scholar 

  12. Kallini JR, Gabr A, Thorlund K, Balijepalli C, Ayres D, Kanters S, et al. Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review. Cardiovasc Intervent Radiol. 2017 Jul 1;40(7):1033–43.

    Article  PubMed  Google Scholar 

  13. Bozkurt MF, Salanci BV, Uğur Ö. Intra-Arterial Radionuclide Therapies for Liver Tumors. Semin Nucl Med. 2016 Jul;46(4):324–39.

    Article  PubMed  Google Scholar 

  14. Ariel IM. Treatment of Inoperable Primary Pancreatic and Liver Cancer by the Intra-Arterial Administration of Radioactive Isotopes (Y Radiating Microspheres). Ann Surg [Internet]. 1965;162(2). Available from: https://journals.lww.com/annalsofsurgery/Fulltext/1965/08000/Treatment_of_Inoperable_Primary_Pancreatic_and.18.aspx

  15. Sirtex - About SIR-Spheres microspheres [Internet]. [cited 2021 Mar 31]. Available from: https://www.sirtex.com/us/patients/about-sir-spheres-microspheres/

  16. TheraSphereTM Y-90 Glass Microspheres [Internet]. www.bostonscientific.com. [cited 2021 Mar 31]. Available from: https://www.bostonscientific.com/en-US/products/cancer-therapies/therasphere-y90-glass-microspheres.html

  17. Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Kulik L, et al. Radioembolization with 90 Y Microspheres: Angiographic and Technical Considerations. Cardiovasc Intervent Radiol. 2007 Jul 1;30(4):571–92.

    Article  PubMed  Google Scholar 

  18. Malhotra A, Liu DM, Talenfeld AD. Radiation Segmentectomy and Radiation Lobectomy: A Practical Review of Techniques. Tech Vasc Interv Radiol. 2019 Jun;22(2):49–57.

    Article  PubMed  Google Scholar 

  19. Uliel L, Royal HD, Darcy MD, Zuckerman DA, Sharma A, Saad NE. From the Angio Suite to the -Camera: Vascular Mapping and 99mTc-MAA Hepatic Perfusion Imaging Before Liver Radioembolization--A Comprehensive Pictorial Review. J Nucl Med. 2012 Nov 1;53(11):1736–47.

    Article  CAS  PubMed  Google Scholar 

  20. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013 Mar;57(3):1078–87.

    Article  CAS  PubMed  Google Scholar 

  21. Puranik AD, Rangarajan V, Gosavi A, Shetty N, Gala K, Kulkarni S, et al. Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization. Nucl Med Commun [Internet]. 2020 Dec 9 [cited 2021 Mar 31];Publish Ahead of Print. Available from: https://journals.lww.com/10.1097/MNM.0000000000001334

  22. Son MH, Ha LN, Bang MH, Bae S, Giang DT, Thinh NT, et al. Diagnostic and prognostic value of 99mTc-MAA SPECT/CT for treatment planning of 90Y-resin microsphere radioembolization for hepatocellular carcinoma: comparison with planar image. Sci Rep. 2021 Dec;11(1):3207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mirka H, Duras P, Baxa J, Korcakova E, Ferda J. Contribution of Computed Tomographic Angiography to Pretreatment Planning of Radio-embolization of Liver Tumors. Anticancer Res. 2018 Jul;38(7):3825–9.

    Article  CAS  PubMed  Google Scholar 

  24. Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther. 2016;33:699–714.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009 Apr;49(4):1185–93.

    Article  PubMed  Google Scholar 

  26. Mora RA, Ali R, Gabr A, Abouchaleh N, Asadi AA, Kallini JR, et al. Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma. Abdom Radiol. 2018 Jul;43(7):1723–38.

    Article  Google Scholar 

  27. Ghosn M, Derbel H, Kharrat R, Oubaya N, Mulé S, Chalaye J, et al. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging. 2021 Jan;102(1):35–44.

    Article  CAS  PubMed  Google Scholar 

  28. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011 Dec;55(6):1309–16.

    Article  PubMed  Google Scholar 

  29. Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib: Vouche et al. Hepatology. 2013 Nov;58(5):1655–66.

  30. Kim Y, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, et al. Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. Curr Oncol. 2021 Feb 21;28(1):965–77.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Nam JY, Lee YB, Lee J-H, Yu SJ, Kim H-C, Chung JW, et al. A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC. Dig Dis Sci [Internet]. 2021 Feb 4 [cited 2021 Mar 31]; Available from: http://link.springer.com/10.1007/s10620-021-06843-4

  32. Mohamed M, Katz AW, Tejani MA, Sharma AK, Kashyap R, Noel MS, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 2016 Jan;1(1):35–42.

    Article  PubMed  Google Scholar 

  33. Bester L, Hobbins PG, Wang S, Salem R. Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer: Imaging findings after 90Y microsphere SIRT. J Med Imaging Radiat Oncol. 2011 Apr;55(2):111–8.

    Article  PubMed  Google Scholar 

  34. Miller FH, Keppke AL, Reddy D, Huang J, Jin J, Mulcahy MF, et al. Response of Liver Metastases After Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET. Am J Roentgenol. 2007 Mar;188(3):776–83.

    Article  Google Scholar 

  35. Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, et al. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver. 2020 Nov 15;14(6):765–74.

  36. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology. 2010 Jan;138(1):52–64.

    Article  CAS  PubMed  Google Scholar 

  37. Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, et al. Multimodality Imaging Following 90 Y Radioembolization: A Comprehensive Review and Pictorial Essay. RadioGraphics. 2008 Jan;28(1):81–99.

    Article  PubMed  Google Scholar 

  38. Keppke AL, Salem R, Reddy D, Huang J, Jin J, Larson AC, et al. Imaging of Hepatocellular Carcinoma After Treatment with Yttrium-90 Microspheres. Am J Roentgenol. 2007 Mar;188(3):768–75.

    Article  Google Scholar 

  39. Semaan S, Makkar J, Lewis S, Chatterji M, Kim E, Taouli B. Imaging of Hepatocellular Carcinoma Response After 90 Y Radioembolization. Am J Roentgenol. 2017 Nov;209(5):W263–76.

    Article  Google Scholar 

  40. Spina JC, Hume I, Pelaez A, Peralta O, Quadrelli M, Garcia Monaco R. Expected and Unexpected Imaging Findings after 90 Y Transarterial Radioembolization for Liver Tumors. RadioGraphics. 2019 Mar;39(2):578–95.

    Article  PubMed  Google Scholar 

  41. American College of Radiology. Liver Imaging Reporting and Data System (LI-RADS) [Internet]. Liver Imaging Reporting and Data System (LI-RADS), American College of Radiology. [cited 2021 Mar 31]. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS

  42. Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlation. J Hepatol. 2011 Apr;54(4):695–704.

    Article  PubMed  Google Scholar 

  43. Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):580–3.

    Article  CAS  PubMed  Google Scholar 

  44. Kallini JR, Miller FH, Gabr A, Salem R, Lewandowski RJ. Hepatic imaging following intra-arterial embolotherapy. Abdom Radiol. 2016 Apr;41(4):600–16.

    Article  Google Scholar 

  45. Song JE, Jung KS, Kim DY, Song K, Won JY, Lee HW, et al. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Int J Radiat Oncol. 2017 Oct;99(2):396–406.

    Article  Google Scholar 

  46. Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski RJ, Salem R, et al. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma: HEPATOBILIARY MALIGNANCIES. Hepatology. 2015 Oct;62(4):1111–21.

    Article  CAS  PubMed  Google Scholar 

  47. Choi H, Charnsangavej C, Faria S de C, Tamm EP, Benjamin RS, Johnson MM, et al. CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A Quantitative Analysis Correlated with FDG PET Findings. Am J Roentgenol. 2004 Dec;183(6):1619–28.

  48. Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, et al. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma. Oncol Lett. 2013 Dec;6(6):1707–12.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Kaplan E, Kaplan S. Computed tomographic perfusion imaging for the prediction of response transarterial radioembolization with Yttrium‑90 glass microspheres of hepatocellular carcinoma. :10.

  50. Kokabi N, Camacho JC, Xing M, Qiu D, Kitajima H, Mittal PK, et al. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. Abdom Imaging. 2014 Oct 1;39(5):969–78.

    Article  PubMed  Google Scholar 

  51. Gordic S, Wagner M, Zanato R, Hectors S, Besa C, Kihira S, et al. Prediction of hepatocellular carcinoma response to 90Yttrium radioembolization using volumetric ADC histogram quantification: preliminary results. Cancer Imaging [Internet]. 2019 May 29 [cited 2021 Mar 31];19. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541997/

  52. Hectors SJ, Lewis S, Kennedy P, Bane O, Said D, Segall M, et al. Assessment of Hepatocellular Carcinoma Response to 90 Y Radioembolization Using Dynamic Contrast Material–enhanced MRI and Intravoxel Incoherent Motion Diffusion-weighted Imaging. Radiol Imaging Cancer. 2020 Jul 1;2(4):e190094.

    Article  PubMed  PubMed Central  Google Scholar 

  53. 53. Mendiratta-Lala M, Masch WR, Shampain K, Zhang A, Jo AS, Moorman S, et al. MRI Assessment of Hepatocellular Carcinoma after Local-Regional                    Therapy: A Comprehensive Review. Radiol Imaging Cancer. 2020 Jan 1;2(1):e190024.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Ibrahim SM, Nikolaidis P, Miller FH, Lewandowski RJ, Ryu RK, Sato KT, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging. 2009 Sep;34(5):566–81.

    Article  PubMed  Google Scholar 

  55. Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, et al. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol. 2020 Oct 27;12(10):738–53.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Amin P, Ness J, Brown M, Sullivan I. Deciphering Liver Imaging After Interventional Oncology Treatments for Hepatocellular Carcinoma. Contemp Diagn Radiol. 2021 Mar 31;44(7):1–7.

    Article  Google Scholar 

  57. Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, et al. Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres. Dig Dis Sci. 2008 Sep;53(9):2556–63.

    Article  CAS  PubMed  Google Scholar 

  58. Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization. Ann Surg Oncol. 2009 Jun;16(6):1587–96.

    Article  PubMed  Google Scholar 

  59. Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, et al. 90 Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes: Liver Resection After 90 Y Radiation Lobectomy. J Surg Oncol. 2016 Jul;114(1):99–105.

    Article  PubMed  Google Scholar 

  60. Singh P, Anil G. Yttrium-90 radioembolization of liver tumors: what do the images tell us? Cancer Imaging. 2013;13(4):645–57.

    Article  Google Scholar 

  61. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, et al. Biliary Sequelae following Radioembolization with Yttrium-90 Microspheres. J Vasc Interv Radiol. 2008 May;19(5):691–7.

    Article  PubMed  Google Scholar 

  62. Korkmaz M, Bozkaya H, Çınar C, Şanal B, Güneyli S, Parıldar M, et al. Liver abscess following radioembolization with yttrium-90 microspheres. Wien Klin Wochenschr. 2014 Dec;126(23–24):785–8.

    Article  PubMed  Google Scholar 

  63. Mascarenhas N, Ryu R, Salem R. Hepatic Radioembolization Complicated by Abscess. Semin Interv Radiol. 2011 Jun;28(02):222–5.

    Article  Google Scholar 

  64. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: Description and possible risk factors. Cancer. 2008 Apr 1;112(7):1538–46.

    Article  PubMed  Google Scholar 

  65. Kim J, Jung Y. Radiation-induced liver disease: current understanding and future perspectives. Exp Mol Med. 2017 Jul;49(7):e359.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Sugi MD, Menias CO, Lubner MG, Bhalla S, Mellnick VM, Kwon MH, et al. CT Findings of Acute Small-Bowel Entities. RadioGraphics. 2018 Sep 1;38(5):1352–69.

    Article  PubMed  Google Scholar 

  67. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, et al. Gastrointestinal Complications Associated with Hepatic Arterial Yttrium-90 Microsphere Therapy. J Vasc Interv Radiol. 2007 Apr;18(4):553–61.

    Article  PubMed  Google Scholar 

  68. Kothari S, Li Y, Almouradi T, Berkelhammer C. Radiation Gastritis Associated With Yttrium-90 Microsphere Radioembolization: 2647. Off J Am Coll Gastroenterol ACG. 2018 Oct;113:S1472.

    Article  Google Scholar 

  69. Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, et al. Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review. J Vasc Interv Radiol. 2009 Sep;20(9):1121–30.

    Article  PubMed  Google Scholar 

  70. Lam MGEH, Banerjee S, Louie JD, Abdelmaksoud MHK, Iagaru AH, Ennen RE, et al. Root Cause Analysis of Gastroduodenal Ulceration After Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol. 2013 Dec;36(6):1536–47.

    Article  PubMed  Google Scholar 

  71. Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, et al. Gastroduodenal Injury After Radioembolization of Hepatic Tumors. Am J Gastroenterol. 2007 Jun;102(6):1216–20.

    Article  PubMed  Google Scholar 

  72. Naymagon S, Warner RRP, Patel K, Harpaz N, Machac J, Weintraub JL, et al. Gastroduodenal Ulceration Associated with Radioembolization for the Treatment of Hepatic Tumors: An Institutional Experience and Review of the Literature. Dig Dis Sci. 2010 Sep;55(9):2450–8.

    Article  PubMed  Google Scholar 

  73. MDS Nordion Inc. Package Insert, TheraSphere Yttrium 90 Glass Microspheres [Internet]. [cited 2021 Mar 31]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf/h980006c.pdf

  74. Sirtex Medical Limited. SSL-US-13 [Internet]. SSL-US-13, Sirtex Sir-Spheres Y-0 Microspheres. [cited 2021 Mar 31]. Available from: https://www.sirtex.com/media/155126/ssl-us-13.pdf

  75. Tann M, Haste P, Rice M. Do we still need to assess for lung shunt in all Y90 Liver treatment’s ? J Nucl Med. 2019 May 1;60(supplement 1):1315–1315.

  76. Das A, Riaz A, Gabr A, Ali R, Mora R, Al Asadi A, et al. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):807–15.

    Article  PubMed  Google Scholar 

  77. Kwok N, Irani Z, Sheth R, Arellano RS. Hepatopulmonary shunt reduction with bland embolization for yttrium-90 radioembolization. Diagn Interv Imaging. 2016 Mar 1;97(3):369–70.

    Article  CAS  PubMed  Google Scholar 

  78. Schiro BJ, Amour ESt, Harnain C, Gandhi RT. Management of High Hepatopulmonary Shunts in the Setting of Y90 Radioembolization. Tech Vasc Interv Radiol. 2019 Jun 1;22(2):58–62.

  79. Thüring J, Zimmermann M, Bruners P, Pedersoli F, Schulze-Hagen M, Barzakova E, et al. Short-Term Oral Sorafenib for Therapy of Intratumoral Shunts of Hepatocellular Carcinoma to Enable Intraarterial Treatment. Cardiovasc Intervent Radiol. 2019 Oct 1;42(10):1494–9.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Wright CL, Werner JD, Tran JM, Gates VL, Rikabi AA, Shah MH, et al. Radiation Pneumonitis Following Yttrium-90 Radioembolization: Case Report and Literature Review. J Vasc Interv Radiol. 2012 May;23(5):669–74.

    Article  PubMed  Google Scholar 

  81. Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. Radiation-induced lung injury: current evidence. BMC Pulm Med [Internet]. 2021 Jan 6 [cited 2021 Mar 31];21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788688/

  82. Sangro B, Martínez‐Urbistondo D, Bester L, Bilbao JI, Coldwell DM, Flamen P, et al. Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review. Hepatology. 2017;66(3):969–82.

    Article  PubMed  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Radiology, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada

    Zersenay Alem, Timothy E. Murray, Csilla Egri, John Chung, David Liu, Silvia D. Chang & Alison Harris

  2. Department of Abdominal Imaging, University of Texas M.D. Anderson Cancer Centre, Houston, USA

    Khaled M. Elsayes

Authors
  1. Zersenay Alem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy E. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Csilla Egri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Khaled M. Elsayes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Silvia D. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alison Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zersenay Alem.

Ethics declarations

Conflict of interest

Not applicable/None.

Ethical approval

Institutional review board not required for review article

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alem, Z., Murray, T.E., Egri, C. et al. Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma. Abdom Radiol 46, 3596–3614 (2021). https://doi.org/10.1007/s00261-021-03095-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-021-03095-8

Keywords

Search

Navigation